Court Report

    By Sherri Oslick --

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.

Forest Laboratories, Inc. et al. v. Synthon Pharmaceuticals, Inc. et al.
5:08-cv-00150; filed March 20, 2008 in the Eastern District of North Carolina

Infringement of U.S. Patent No. 5,061,703 ("Adamantane Derivatives in the Prevention and Treatment of Cerebral Ischemia," issued on October 29, 1991), following a paragraph IV certification as part of Synthon’s filing of an ANDA to manufacture a generic version of Forest's Namenda® (memantine hydrochloride, used for the treatment of moderate to severe dementia of the Alzheimer's type).  View the complaint here.

Sanofi-Aventis et al. v. Wockhardt Limited et al.
1:08-cv-00150; filed March 14, 2008 in the District Court of Delaware

Infringement of U.S. Patent No. 6,149,940 ("Tablet with Controlled Release of Alfuzosine Chlorhydrate," issued November 21, 2000) following a paragraph IV certification as part of Wockhardt’s filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Uroxatral® (alfuzosin hydrochloride, used to treat benign prostatic hyperplasia).  View the complaint here.

Ortho-McNeil Pharmaceutical, Inc. v. Mylan Pharmaceuticals Inc. et al.
1:08-cv-01343; filed March 5, 2008 in the Northern District of Illinois

Infringement of U.S. Patent No. RE39,221 ("Composition Comprising a Tramadol Material and Acetaminophen and Its Use," issued August 1, 2006) following a paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Ortho-McNeil's Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain).  View the complaint here.